The Role of ctDNA in Colorectal Cancer

March 27th 2025

LaPelusa’s Journey in the Dynamic Field of GI Oncology

A phase 2 trial will evaluate leronlimab’s safety and efficacy for the treatment of patients with microsatellite stable metastatic colorectal cancer.

Jordyn Sava;Michael LaPelusa, MD

May 1st 2024

FDA Grants Orphan Drug Designation to PEP-010 in Pancreatic Cancer

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Listen

March 21st 2025

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

PEP-010 was granted FDA orphan drug designation for the treatment of pancreatic cancer.

Jordyn Sava;Arvind Dasari, MD, MS

November 15th 2023

FDA Grants Orphan Drug Designation to HLX22 for Gastric Cancer Treatment

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

FDA Backs Phase 3 Trial of Pro-ocular for Ocular GVHD Treatment

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line treatment.

Leronlimab Gets FDA Nod for Phase 2 Microsatellite-Stable CRC Trial

A phase 3 trial plans to evaluate Pro-ocular for the treatment of patients with ocular graft-vs-host disease.

Related Content

GI CANCERS

Colorectal Cancer

GI ASCO 2024 Highlights

March 27th 2025

LaPelusa’s Journey in the Dynamic Field of GI Oncology

A phase 2 trial will evaluate leronlimab’s safety and efficacy for the treatment of patients with microsatellite stable metastatic colorectal cancer.

Jordyn Sava;Michael LaPelusa, MD

May 1st 2024

FDA Grants Orphan Drug Designation to PEP-010 in Pancreatic Cancer

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Listen

March 21st 2025

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

PEP-010 was granted FDA orphan drug designation for the treatment of pancreatic cancer.

Jordyn Sava;Arvind Dasari, MD, MS

November 15th 2023

FDA Grants Orphan Drug Designation to HLX22 for Gastric Cancer Treatment

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

FDA Backs Phase 3 Trial of Pro-ocular for Ocular GVHD Treatment

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line treatment.